The incidence of non-alcoholic fatty liver disease (NAFLD) is increasing rapidly worldwide;
however, there are currently limited treatments for NAFLD. The disease spectrum includes …

Non-alcoholic fatty liver disease (NAFLD) has a global prevalence of approximately 25%
and is associated with high morbidity and high mortality. NAFLD is a leading cause of …

Non‐alcoholic fatty liver disease (NAFLD) may vary from moderately mild non‐alcohol fatty
liver (NAFL) towards the malignant variant known as non‐alcoholic steatohepatitis (NASH) …

The contemporary pathophysiological model of non-alcoholic fatty liver disease (NAFLD)
comprises multiple parallel pathways with a dynamic cross talk that cumulate in steatosis …

Over the years, the prevalence of nonalcoholic fatty liver disease (NAFLD) has increased
year by year; however, due to its complicated pathogenesis, there is no effective treatment …

Non-alcoholic fatty liver disease (NAFLD), the hepatic manifestation of metabolic syndrome,
is one of the most common chronic liver diseases, which may progress to fibrosis, cirrhosis …

Ethnopharmacological relevance Plants are a natural treasure trove; their secondary
metabolites participate in several pharmacological processes, making them a crucial …

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease,
affecting approximately one-quarter of the global population, and has become a world public …

Nonalcoholic fatty liver disease (NAFLD), which is characterized by excessive fat
accumulation in the liver of patients who consume little or no alcohol, becomes increasingly …

Non‐alcoholic fatty liver disease (NAFLD) has been known as the hepatic feature of
metabolic syndrome. Extra fat depots, especially in visceral areas, develop insulin …